查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993111

芽生菌病市場：按產品類型、給藥途徑、最終用戶和分銷管道分類的全球市場預測 - 2026-2032 年

Blastomycosis Market by Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，芽生菌病市場價值將達到 1.6757 億美元，到 2026 年將成長至 1.7667 億美元，到 2032 年將達到 2.1224 億美元，年複合成長率為 3.43%。

主要市場統計數據
基準年 2025 1.6757億美元
預計年份：2026年 1.7667億美元
預測年份 2032 2.1224億美元
複合年成長率 (%) 3.43%

針對芽生菌病的臨床和商業性實施指南，重點在於診斷挑戰、治療途徑以及相關人員的策略挑戰。

芽生菌病仍是一種未被充分認知的真菌感染疾病，對臨床診療路徑、診斷流程設計和治療策略產生了深遠的影響。雖然疫情爆發相對局限於特定的流行區域，但特異性症狀和現有檢測方法的局限性給臨床醫生和醫療系統帶來了診斷延遲的巨大挑戰。因此，患者的預後取決於早期識別以及可靠診斷工具和有效抗真菌藥物治療方案的可用性。從商業性角度來看，這些臨床現實迫切需要診斷技術的創新、分子檢測的改進以及標靶治療。

透過新型診斷技術、改良的治療方法和供應鏈調整，重塑芽生菌病治療的臨床路徑和市場機會。

芽生菌病的治療格局正在經歷一場變革，這主要得益於技術進步、監管力度加大以及臨床實踐模式的轉變。分子診斷領域的重大創新提高了檢測的敏感度和速度，使得早期啟動治療成為可能。同時，血清學檢測和影像學檢查結果解讀框架的改善降低了診斷的不確定性，而診斷不確定性歷來是導致治療延遲和預後不良的原因之一。這些診斷技術的不確定性正在重塑臨床路徑，並凸顯了檢查室準備和臨床醫生教育的重要性。

評估 2025 年關稅變化及其對影響芽生菌病相關產品的供應鏈、採購決策和商業策略的實際影響。

2025年的關稅政策變化進一步增加了參與芽生菌病相關診斷和治療藥物生產、進口和分銷的利益相關相關人員的複雜性。某些醫療產品關稅的提高可能會影響單位經濟效益，迫使製造商和經銷商重新評估籌資策略、區域生產地點和合約定價模式。對於經常跨境流通的診斷設備和試劑而言，關稅導致的成本增加可能會導致醫院和檢查室的採購週期延長，因為需要重新評估資金分配決策。

可操作的細分訊息，解釋產品、最終用戶、分銷和管理方法的差異，以促進產品的採用、採購和臨床應用。

市場區隔揭示了產品類型、最終用戶、分銷管道和給藥途徑等關鍵轉折點，這些因素共同決定了市場動態和臨床應用。依產品類型分類，市場大致分為診斷與治療兩大類。診斷產品再細分為影像學、分子檢測和血清學檢測，而治療產品則分為Azole和Polyenes，Azole再細分為Fluconazole和Itraconazole。這些產品層面的區分會影響臨床工作流程、投資重點以及相關人員認可的上市證據類型。

區域差異和策略反映了流行病模式、醫療保健系統和法規環境，從而影響實施準備和需求。

芽生菌病的區域性流行趨勢反映了各主要地區流行病學、醫療基礎設施和法律規範的差異。在美洲，特定地區的流行狀態引起了臨床關注，催生了對快速診斷方法和有效抗真菌藥物的需求。同時，完善的醫院網路和實驗室系統正為採用先進的分子檢測技術鋪路。在歐洲、中東和非洲，監測能力和診斷可近性的差異導致需求多樣化。一些市場優先考慮價格合理的血清學檢測和能力建設，而擁有先進三級醫療中心的市場則專注於尖端分子診斷平台和特效療法。

企業策略和夥伴關係模式揭示了診斷和治療公司如何透過證據產生、供應鏈韌性和臨床參與來脫穎而出。

在企業層面，一個多元化的生態系統正在形成，旨在滿足芽生菌病的臨床需求，該生態系統涵蓋診斷試劑開發商、製藥企業和專業經銷商。一些主要相關人員優先投資於分子診斷平台，透過提高檢測靈敏度和最佳化工作流程來縮短診斷時間；而其他公司則專注於提升血清學檢測性能和增強影像輔助工具。在治療領域，擁有成熟抗真菌藥物產品組合的製造商正致力於最佳化製劑配方、提升安全性，並透過醫學教育和管理專案支持符合指南的用藥。

為領導者提供切實可行的綜合建議，以加快診斷方法的採用，最佳化治療方法的使用，並確保整個市場供應鏈的韌性。

致力於鞏固自身在芽生菌病治療領域地位的產業領導者應優先考慮一系列兼顧臨床價值和商業性可行性的綜合策略。首先，應投資進行嚴謹的診斷檢驗研究，以證明藥物在具有代表性的患者群體中具有真實世界的敏感性和特異性，並將這些證據與臨床醫生教育舉措相結合，從而減少診斷延遲。其次，應最佳化治療方案的實施，考慮以患者為中心的製劑研發進展和清晰的處方指南，以解決安全性和依從性問題，同時與藥物管理計畫合作，以維持治療方案的長期療效。

採用透明、多方面的研究途徑，整合主要臨床發現、權威文獻和嚴格檢驗，以確保提供實用見解。

本研究採用多面向方法，結合一手和二手證據，建構芽生菌病臨床和商業性趨勢的全面圖景。一手資料將透過訪談感染疾病專家、檢查室管理人員、醫院藥劑師和分銷專員收集，以獲取關於診斷性能、治療決策、採購實踐和區域准入障礙的第一手觀點。這些定性研究結果將與同行評審的臨床文獻、監管指導文件和公開的治療指南進行交叉比對，以確保臨床準確性。

該策略結論強調，需要將診斷創新、治療最佳化和強力的商業化聯繫起來，以改善患者的治療效果。

總之，芽生菌病治療領域的不斷演變為能夠協調診斷創新、治療最佳化和穩健商業化策略的相關人員提供了明確的機會。提高診斷速度和準確性仍然是減輕臨床負擔和改善患者預後的最直接途徑。同時，優先考慮安全性、給藥柔軟性和實際應用支援的治療方案將有助於增強所有醫療機構的治療連續性。區域差異凸顯了製定符合當地流行病模式、醫療基礎設施和採購慣例的區域性策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：芽生菌病市場：依產品類型分類

  • 診斷藥物
    • 診斷影像
    • 分子檢測
    • 血清學檢測
  • 治療藥物
    • Azole藥物
      • Fluconazole
      • Itraconazole
    • Polyenes

第9章：芽生菌病市場：依給藥途徑分類

  • 靜脈
  • 口服
    • 膠囊
    • 口服液體藥物

第10章：芽生菌病市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院

第11章：芽生菌病市場：依通路分類

  • 直接競標
  • 銷售代理
  • 線上零售

第12章：芽生菌病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：芽生菌病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：芽生菌病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國芽生菌病市場

第16章：中國芽生菌病市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amphastar Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Celltrion Healthcare Co., Ltd.
  • CSL Limited
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • IMMY, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck & Co., Inc.
  • Meridian Bioscience, Inc.
  • MycoMed Technologies
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
  • Viatris Inc.
Product Code: MRR-1A1A064C0289

The Blastomycosis Market was valued at USD 167.57 million in 2025 and is projected to grow to USD 176.67 million in 2026, with a CAGR of 3.43%, reaching USD 212.24 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 167.57 million
Estimated Year [2026] USD 176.67 million
Forecast Year [2032] USD 212.24 million
CAGR (%) 3.43%

A focused clinical and commercial introduction to blastomycosis emphasizing diagnostic hurdles, therapeutic pathways, and strategic imperatives for stakeholders

Blastomycosis remains an underrecognized fungal infection with outsized implications for clinical pathways, diagnostic workflow design, and therapeutic strategy. Although incidence is relatively localized in endemic regions, clinicians and health systems face significant diagnostic delays owing to nonspecific presentations and limitations in current testing modalities. Consequently, patient outcomes hinge on timely recognition and the availability of reliable diagnostic tools paired with effective antifungal regimens. From a commercial perspective, these clinical realities translate into distinct demand drivers for diagnostics innovation, improved molecular assays, and targeted therapeutics.

In addition, evolving awareness among frontline clinicians and public health authorities is beginning to reshape detection efforts, which in turn affects procurement cycles and formulary decisions. Diagnostic laboratories and hospitals must balance speed, sensitivity, and cost when selecting tests, while ambulatory care settings increasingly require accessible point-of-care solutions. Therapeutic selection is influenced by route of administration, patient comorbidities, and tolerability, with oral azoles and intravenous polyenes continuing to play established roles. Taken together, these dynamics create an environment where strategic investment in diagnostic accuracy and therapeutic optimization offers the greatest potential for clinical and commercial impact.

Emerging diagnostic innovations, therapeutic refinements, and supply chain adaptations reshaping clinical pathways and market opportunities in blastomycosis care

The landscape for blastomycosis is undergoing transformative shifts driven by technological advances, regulatory attention, and changing clinical practice patterns. Key innovations in molecular diagnostics are increasing the sensitivity and speed of detection, enabling earlier initiation of therapy. Simultaneously, refinements in serological assays and imaging interpretation frameworks are helping to reduce diagnostic uncertainty, which historically contributed to treatment delays and poorer outcomes. These diagnostic improvements are reshaping clinical pathways and elevating the importance of laboratory readiness and clinician education.

On the therapeutic front, stewardship considerations and evolving evidence on azole efficacy and safety are prompting more nuanced prescribing practices. The balance between oral and intravenous administration is influenced by patient acuity and care setting, while formulation improvements aim to enhance adherence and tolerability. Moreover, supply chain resilience and distribution channel optimization are becoming strategic priorities as stakeholders seek to ensure uninterrupted access to critical diagnostics and antifungals. Together, these trends are converging to create new opportunities for diagnostic manufacturers, pharmaceutical developers, and health systems to collaborate on integrated care models that reduce time-to-diagnosis and improve patient outcomes.

Assessment of 2025 tariff shifts and their practical implications for supply chains, procurement decisions, and commercial strategies impacting blastomycosis products

Tariff policy changes in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, importation, and distribution of diagnostics and therapeutics relevant to blastomycosis. Increased duties on certain medical goods can influence unit economics, prompting manufacturers and distributors to reassess sourcing strategies, regional production footprints, and contractual pricing models. For diagnostic equipment and reagents that cross borders frequently, tariff-induced cost inflation can translate into delayed procurement cycles for hospitals and laboratories as capital allocation decisions are revisited.

At the same time, therapeutics that depend on international raw materials or finished-good imports face potential margin pressure that may affect availability or lead to preferential stocking of domestically produced alternatives where feasible. In response, many firms are intensifying efforts to localize supply chains, diversify supplier bases, and negotiate longer-term purchasing agreements to stabilize costs. Payers and purchasing groups are likely to play a more prominent role in mediating access and cost-containment, and manufacturers will need to align commercial strategies with evolving reimbursement conversations and procurement tender practices to preserve market access amid tariff volatility.

Actionable segmentation intelligence describing product, end-user, distribution, and administration distinctions that drive adoption, procurement, and clinical use

Segmentation reveals critical inflection points across product types, end users, distribution channels, and administration routes that collectively define market dynamics and clinical adoption. Based on Product Type, the landscape spans Diagnostics and Therapeutics, with Diagnostics further differentiated by Imaging, Molecular Test, and Serological Test, and Therapeutics further divided into Azoles and Polyenes, with Azoles also split between Fluconazole and Itraconazole. These product-level distinctions influence clinical workflows, investment priorities, and the types of evidence stakeholders will accept for adoption.

Based on End User, demand patterns vary across Ambulatory Care Settings, Diagnostic Laboratories, and Hospitals, each with distinct purchasing cycles, volume requirements, and clinical priorities. Based on Distribution Channel, procurement and logistics differ when sourced via Direct Tender, Distributor, or Online Retail, affecting time-to-market and inventory management. Based on Route Of Administration, choices between Intravenous and Oral therapies shape inpatient versus outpatient treatment pathways, and the Oral category itself is further delineated into Capsules and Oral Solution, which have implications for adherence, dosing flexibility, and patient preference. Understanding these intersecting segmentation dimensions enables more precise targeting of clinical evidence generation, commercialization tactics, and supply chain design.

Geographic differentiation and regional strategies reflecting endemic patterns, healthcare capabilities, and regulatory environments that shape readiness and demand

Regional dynamics for blastomycosis reflect divergent epidemiology, healthcare infrastructure, and regulatory frameworks across major geographies. In the Americas, endemicity in certain regions drives concentrated clinical awareness, shaping demand for rapid diagnostics and effective antifungal options, while established hospital networks and laboratory systems create pathways for adoption of advanced molecular assays. In Europe, Middle East & Africa, variable surveillance capacity and differential access to diagnostics lead to heterogeneous needs; some markets prioritize affordable serological tests and capacity building, whereas others with advanced tertiary centers focus on cutting-edge molecular platforms and specialist therapeutics.

In the Asia-Pacific region, increasing investment in laboratory infrastructure, rising clinician familiarity with fungal infections, and expanding private-sector distribution networks are fueling opportunities for both diagnostics and therapeutics. Cross-regionally, regulatory harmonization, reimbursement mechanisms, and supply chain resilience emerge as common themes that influence how products are introduced and scaled. Consequently, tailored regional strategies that account for endemicity, healthcare delivery models, and payer environments are essential for successful market entry and sustained uptake.

Corporate strategies and partnership models revealing how diagnostics and therapeutics players differentiate through evidence generation, supply resilience, and clinical engagement

Company-level dynamics show a diverse ecosystem of diagnostic developers, pharmaceutical manufacturers, and specialized distributors engaged in addressing blastomycosis clinical needs. Leading stakeholders that prioritize investment in molecular diagnostic platforms are accelerating time-to-diagnosis through assay sensitivity and workflow integration, while others focus on improving serology performance and imaging interpretation support tools. On the therapeutics side, manufacturers with established antifungal portfolios concentrate on optimizing formulations, improving safety profiles, and supporting guideline-compliant use through medical education and stewardship programs.

Strategic partnerships between diagnostic companies and clinical networks are becoming more common, enabling validation studies and smoother adoption pathways. Similarly, collaborations between pharmaceutical firms and hospital systems can support real-world evidence generation and formulary inclusion. Competitive differentiation increasingly rests on the ability to demonstrate clinical utility, cost-effectiveness, and supply reliability. As a result, companies investing in clinician outreach, robust post-market surveillance, and flexible distribution arrangements are better positioned to capture clinical trust and long-term institutional relationships.

Pragmatic and integrated recommendations for leaders to accelerate diagnostic adoption, optimize therapeutic use, and secure resilient supply chains across markets

Industry leaders seeking to strengthen their position in blastomycosis care should prioritize a set of integrated actions that align clinical value with commercial viability. First, invest in robust diagnostic validation studies that demonstrate real-world sensitivity and specificity across representative patient cohorts, and pair that evidence with clinician-facing educational initiatives to reduce diagnostic delay. Second, optimize therapeutic offerings by considering patient-centric formulation advances and clear prescribing guidance that addresses safety and adherence concerns, while coordinating with stewardship programs to preserve therapeutic longevity.

Third, fortify supply chain resilience through supplier diversification, localized manufacturing where feasible, and flexible distribution agreements that mitigate tariff and logistic risks. Fourth, tailor market entry and scaling strategies to regional healthcare systems by aligning regulatory strategies, reimbursement dossiers, and local clinical champions. Fifth, engage in collaborative partnerships across diagnostics, therapeutics, and hospital networks to build integrated care pathways that shorten time-to-diagnosis and improve outcomes. Implementing these steps with clear KPIs and cross-functional governance will translate strategic intent into measurable impact.

Transparent multi-method research approach integrating primary clinical insights, authoritative literature synthesis, and rigorous validation to ensure actionable findings

This research adopts a multi-method approach combining primary and secondary evidence streams to construct a comprehensive view of blastomycosis clinical and commercial dynamics. Primary inputs include interviews with infectious disease clinicians, laboratory directors, hospital pharmacists, and distribution specialists to capture firsthand perspectives on diagnostic performance, therapeutic decision-making, procurement practices, and regional access barriers. These qualitative insights are triangulated with peer-reviewed clinical literature, regulatory guidance documents, and publicly available treatment guidelines to ensure clinical accuracy.

Analytical methods encompass segmentation analysis to delineate meaningful clinical and commercial cohorts, scenario planning to assess supply chain and tariff impacts, and company profiling to map strategic positioning and partnership activity. Data validation steps include cross-checking interview findings against published studies and regulatory sources, as well as reconciling discrepancies through follow-up conversations. The methodology emphasizes transparency, reproducibility, and relevance to decision-makers, and it is designed to support both strategic planning and operational implementation.

Strategic conclusion emphasizing the imperative for coordinated diagnostic innovation, therapeutic optimization, and resilient commercialization to improve patient outcomes

In conclusion, the evolving landscape of blastomycosis care presents clear opportunities for stakeholders who can align diagnostic innovation, therapeutic optimization, and resilient commercialization strategies. Improving diagnostic speed and accuracy remains the most direct lever to reduce clinical burden and improve patient outcomes, while therapeutic choices that prioritize safety, administration flexibility, and real-world support will enhance care continuity across settings. Regional differences underscore the need for bespoke approaches that reflect endemic patterns, healthcare infrastructure, and procurement norms.

Furthermore, recent tariff dynamics and supply chain pressures highlight the strategic importance of sourcing flexibility and distribution agility. Companies that invest in evidence generation, clinician engagement, and operational robustness will be best positioned to translate scientific advances into clinical adoption and institutional trust. Ultimately, coordinated action across manufacturers, health systems, and policymakers is required to close gaps in detection and treatment, and to ensure that patients receive timely, effective care regardless of geography.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blastomycosis Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Imaging
    • 8.1.2. Molecular Test
    • 8.1.3. Serological Test
  • 8.2. Therapeutics
    • 8.2.1. Azoles
      • 8.2.1.1. Fluconazole
      • 8.2.1.2. Itraconazole
    • 8.2.2. Polyenes

9. Blastomycosis Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Oral Solution

10. Blastomycosis Market, by End User

  • 10.1. Ambulatory Care Settings
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals

11. Blastomycosis Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distributor
  • 11.3. Online Retail

12. Blastomycosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blastomycosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blastomycosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blastomycosis Market

16. China Blastomycosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amphastar Pharmaceuticals, Inc.
  • 17.7. Astellas Pharma Inc.
  • 17.8. Bayer AG
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. BioMerieux SA
  • 17.11. Celltrion Healthcare Co., Ltd.
  • 17.12. CSL Limited
  • 17.13. Fresenius Kabi AG
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Hikma Pharmaceuticals plc
  • 17.17. IMMY, Inc.
  • 17.18. Johnson & Johnson
  • 17.19. Luminex Corporation
  • 17.20. Merck & Co., Inc.
  • 17.21. Meridian Bioscience, Inc.
  • 17.22. MycoMed Technologies
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Sandoz International GmbH
  • 17.26. Sanofi S.A.
  • 17.27. Sun Pharmaceutical Industries Ltd.
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. Thermo Fisher Scientific, Inc.
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLASTOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLASTOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SEROLOGICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BLASTOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BLASTOMYCOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BLASTOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BLASTOMYCOSIS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)